Drugs interactions for Vivitrol ®

  • 32 Major drug interactions (including ingredients like Alfentanil, Benzhydrocodone, Bremelanotide)
  • 205 Moderate drug interactions (including ingredients like Acetazolamide, Aclidinium, Adenine)
  • 52 Minor drug interactions (including ingredients like Acamprosate, Bisacodyl, Calcium polycarbophil)
289 interactions for Vivitrol ®
A therapy excluded from this list of known interactions does not necessarily mean that no interactions exist between that therapy and and Vivitrol ®.
Alfentanil
The therapeutic efficacy of Alfentanil can be decreased when used in combination with Naltrexone.
Benzhydrocodone
The therapeutic efficacy of Benzhydrocodone can be decreased when used in combination with Naltrexone.
Bremelanotide
The serum concentration of Naltrexone can be decreased when it is combined with Bremelanotide.
Buprenorphine
The therapeutic efficacy of Buprenorphine can be decreased when used in combination with Naltrexone.
Butorphanol
The therapeutic efficacy of Butorphanol can be decreased when used in combination with Naltrexone.
Codeine
The therapeutic efficacy of Codeine can be decreased when used in combination with Naltrexone.
Dextropropoxyphene
The therapeutic efficacy of Dextropropoxyphene can be decreased when used in combination with Naltrexone.
Dihydrocodeine
The therapeutic efficacy of Dihydrocodeine can be decreased when used in combination with Naltrexone.
Diphenoxylate
The therapeutic efficacy of Diphenoxylate can be decreased when used in combination with Naltrexone.
Eluxadoline
The therapeutic efficacy of Eluxadoline can be decreased when used in combination with Naltrexone.
Ethanol
The risk or severity of adverse effects can be increased when Ethanol is combined with Naltrexone.
Fentanyl
The therapeutic efficacy of Fentanyl can be decreased when used in combination with Naltrexone.
Hydrocodone
The therapeutic efficacy of Hydrocodone can be decreased when used in combination with Naltrexone.
Hydromorphone
The therapeutic efficacy of Hydromorphone can be decreased when used in combination with Naltrexone.
Levorphanol
The therapeutic efficacy of Levorphanol can be decreased when used in combination with Naltrexone.
Meperidine
The therapeutic efficacy of Meperidine can be decreased when used in combination with Naltrexone.
Methadone
The therapeutic efficacy of Methadone can be decreased when used in combination with Naltrexone.
Methylnaltrexone
Naltrexone may increase the opioid antagonism activities of Methylnaltrexone.
Morphine
The therapeutic efficacy of Morphine can be decreased when used in combination with Naltrexone.
Nalbuphine
The therapeutic efficacy of Nalbuphine can be decreased when used in combination with Naltrexone.
Naloxegol
The therapeutic efficacy of Naloxegol can be decreased when used in combination with Naltrexone.
Naloxone
The therapeutic efficacy of Naltrexone can be decreased when used in combination with Naloxone.
Oliceridine
The therapeutic efficacy of Oliceridine can be decreased when used in combination with Naltrexone.
Opium
The therapeutic efficacy of Opium can be decreased when used in combination with Naltrexone.
Oxycodone
The therapeutic efficacy of Oxycodone can be decreased when used in combination with Naltrexone.
Oxymorphone
The therapeutic efficacy of Oxymorphone can be decreased when used in combination with Naltrexone.
Pentazocine
The therapeutic efficacy of Pentazocine can be decreased when used in combination with Naltrexone.
Pexidartinib
Naltrexone may increase the hepatotoxic activities of Pexidartinib.
Remifentanil
The therapeutic efficacy of Remifentanil can be decreased when used in combination with Naltrexone.
Sufentanil
The therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.
Tapentadol
The therapeutic efficacy of Tapentadol can be decreased when used in combination with Naltrexone.
Tramadol
The therapeutic efficacy of Tramadol can be decreased when used in combination with Naltrexone.
Acetazolamide
The therapeutic efficacy of Acetazolamide can be decreased when used in combination with Naltrexone.
Aclidinium
The risk or severity of adverse effects can be increased when Aclidinium is combined with Naltrexone.
Adenine
The metabolism of Naltrexone can be decreased when combined with Adenine.
Alprazolam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Alprazolam.
Alvimopan
The risk or severity of adverse effects can be increased when Naltrexone is combined with Alvimopan.
Amantadine
The risk or severity of adverse effects can be increased when Amantadine is combined with Naltrexone.
Amiloride
The therapeutic efficacy of Amiloride can be decreased when used in combination with Naltrexone.
Amitriptyline
The risk or severity of adverse effects can be increased when Amitriptyline is combined with Naltrexone.
Amobarbital
The risk or severity of adverse effects can be increased when Amobarbital is combined with Naltrexone.
Amoxapine
The risk or severity of adverse effects can be increased when Amoxapine is combined with Naltrexone.
Amphetamine
Amphetamine may increase the analgesic activities of Naltrexone.
Aripiprazole
The risk or severity of adverse effects can be increased when Aripiprazole is combined with Naltrexone.
Asciminib
The metabolism of Naltrexone can be decreased when combined with Asciminib.
Atazanavir
The metabolism of Naltrexone can be decreased when combined with Atazanavir.
Atracurium besylate
The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Naltrexone.
Atropine
The risk or severity of adverse effects can be increased when Atropine is combined with Naltrexone.
Baclofen
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Baclofen.
Belladonna
The risk or severity of adverse effects can be increased when Belladonna is combined with Naltrexone.
Bendroflumethiazide
The therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Naltrexone.
Benzatropine
The risk or severity of adverse effects can be increased when Benzatropine is combined with Naltrexone.
Benzphetamine
Benzphetamine may increase the analgesic activities of Naltrexone.
Botulinum toxin type B
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Botulinum toxin type B.
Bromotheophylline
The therapeutic efficacy of Bromotheophylline can be decreased when used in combination with Naltrexone.
Brompheniramine
The risk or severity of adverse effects can be increased when Brompheniramine is combined with Naltrexone.
Bumetanide
The therapeutic efficacy of Bumetanide can be decreased when used in combination with Naltrexone.
Butalbital
The risk or severity of adverse effects can be increased when Butalbital is combined with Naltrexone.
Carbamazepine
The metabolism of Naltrexone can be increased when combined with Carbamazepine.
Carisoprodol
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Carisoprodol.
Chlordiazepoxide
The risk or severity of adverse effects can be increased when Naltrexone is combined with Chlordiazepoxide.
Chlorothiazide
The therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Naltrexone.
Chlorpromazine
The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Naltrexone.
Chlorthalidone
The therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Naltrexone.
Chlorzoxazone
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Chlorzoxazone.
Cisatracurium
The risk or severity of adverse effects can be increased when Cisatracurium is combined with Naltrexone.
Citalopram
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Citalopram.
Clidinium
The risk or severity of adverse effects can be increased when Clidinium is combined with Naltrexone.
Clobazam
The risk or severity of respiratory depression can be increased when Clobazam is combined with Naltrexone.
Clonazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Clonazepam.
Clonidine
The risk or severity of hypotension can be increased when Naltrexone is combined with Clonidine.
Clopidogrel
Naltrexone can cause a decrease in the absorption of Clopidogrel resulting in a reduced serum concentration and potentially a decrease in efficacy.
Clorazepic acid
The risk or severity of adverse effects can be increased when Naltrexone is combined with Clorazepic acid.
Clozapine
The risk or severity of adverse effects can be increased when Clozapine is combined with Naltrexone.
Cocaine
The risk or severity of adverse effects can be increased when Cocaine is combined with Naltrexone.
Conivaptan
The therapeutic efficacy of Conivaptan can be decreased when used in combination with Naltrexone.
Cyclobenzaprine
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Cyclobenzaprine.
Cyproheptadine
The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Naltrexone.
Dabrafenib
The metabolism of Naltrexone can be decreased when combined with Dabrafenib.
Dacomitinib
The metabolism of Naltrexone can be decreased when combined with Dacomitinib.
Dantrolene
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Dantrolene.
Darifenacin
The risk or severity of adverse effects can be increased when Darifenacin is combined with Naltrexone.
Dasabuvir
The metabolism of Naltrexone can be decreased when combined with Dasabuvir.
Defactinib
The metabolism of Naltrexone can be decreased when combined with Defactinib.
Deferasirox
The metabolism of Naltrexone can be decreased when combined with Deferasirox.
Desipramine
The risk or severity of adverse effects can be increased when Desipramine is combined with Naltrexone.
Desloratadine
The risk or severity of adverse effects can be increased when Desloratadine is combined with Naltrexone.
Desogestrel
The metabolism of Naltrexone can be increased when combined with Desogestrel.
Desvenlafaxine
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Desvenlafaxine.
Dextroamphetamine
Dextroamphetamine may increase the analgesic activities of Naltrexone.
Dextromethorphan
The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Naltrexone.
Diazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Diazepam.
Diclofenamide
The therapeutic efficacy of Diclofenamide can be decreased when used in combination with Naltrexone.
Dicyclomine
The risk or severity of adverse effects can be increased when Dicyclomine is combined with Naltrexone.
Diethylpropion
Diethylpropion may increase the analgesic activities of Naltrexone.
Diphenhydramine
The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Naltrexone.
Disopyramide
The risk or severity of adverse effects can be increased when Disopyramide is combined with Naltrexone.
Donepezil
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Donepezil.
Doxepin
The risk or severity of adverse effects can be increased when Doxepin is combined with Naltrexone.
Doxylamine
The risk or severity of adverse effects can be increased when Doxylamine is combined with Naltrexone.
Drospirenone
The therapeutic efficacy of Drospirenone can be decreased when used in combination with Naltrexone.
Duloxetine
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Duloxetine.
Efavirenz
The metabolism of Naltrexone can be increased when combined with Efavirenz.
Eltrombopag
The metabolism of Naltrexone can be decreased when combined with Eltrombopag.
Enasidenib
The metabolism of Naltrexone can be decreased when combined with Enasidenib.
Encorafenib
The metabolism of Naltrexone can be decreased when combined with Encorafenib.
Eplerenone
The therapeutic efficacy of Eplerenone can be decreased when used in combination with Naltrexone.
Erlotinib
The metabolism of Naltrexone can be decreased when combined with Erlotinib.
Escitalopram
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Escitalopram.
Estazolam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Estazolam.
Eszopiclone
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Eszopiclone.
Etacrynic acid
The therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Naltrexone.
Ethinylestradiol
The metabolism of Naltrexone can be increased when combined with Ethinylestradiol.
Fesoterodine
The risk or severity of adverse effects can be increased when Fesoterodine is combined with Naltrexone.
Finerenone
The therapeutic efficacy of Finerenone can be decreased when used in combination with Naltrexone.
Flavoxate
The risk or severity of adverse effects can be increased when Flavoxate is combined with Naltrexone.
Fluoxetine
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluoxetine.
Fluphenazine
The risk or severity of hypotension and CNS depression can be increased when Fluphenazine is combined with Naltrexone.
Flurazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Flurazepam.
Flurbiprofen
The metabolism of Naltrexone can be decreased when combined with Flurbiprofen.
Fluvoxamine
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Fluvoxamine.
Fostamatinib
The metabolism of Naltrexone can be decreased when combined with Fostamatinib.
Furosemide
The therapeutic efficacy of Furosemide can be decreased when used in combination with Naltrexone.
Gemfibrozil
The metabolism of Naltrexone can be decreased when combined with Gemfibrozil.
Glecaprevir
The metabolism of Naltrexone can be decreased when combined with Glecaprevir.
Glycopyrronium
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Naltrexone.
Homatropine methylbromide
The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Naltrexone.
Hydrochlorothiazide
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naltrexone.
Hydroflumethiazide
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naltrexone.
Hyoscyamine
The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Naltrexone.
Imipramine
The risk or severity of adverse effects can be increased when Imipramine is combined with Naltrexone.
Indapamide
The therapeutic efficacy of Indapamide can be decreased when used in combination with Naltrexone.
Indinavir
The metabolism of Naltrexone can be decreased when combined with Indinavir.
Indomethacin
The metabolism of Naltrexone can be decreased when combined with Indomethacin.
Ipratropium
The risk or severity of adverse effects can be increased when Ipratropium is combined with Naltrexone.
Isoflurane
The risk or severity of adverse effects can be increased when Isoflurane is combined with Naltrexone.
Isosorbide
The therapeutic efficacy of Isosorbide can be decreased when used in combination with Naltrexone.
Ketoconazole
The metabolism of Naltrexone can be decreased when combined with Ketoconazole.
Lamotrigine
The metabolism of Naltrexone can be increased when combined with Lamotrigine.
Lisdexamfetamine
Lisdexamfetamine may increase the analgesic activities of Naltrexone.
Lofexidine
The bioavailability of Naltrexone can be decreased when combined with Lofexidine.
Lorazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Lorazepam.
Mannitol
The therapeutic efficacy of Mannitol can be decreased when used in combination with Naltrexone.
Maprotiline
The risk or severity of adverse effects can be increased when Maprotiline is combined with Naltrexone.
Mecamylamine
The risk or severity of adverse effects can be increased when Mecamylamine is combined with Naltrexone.
Meclizine
The risk or severity of adverse effects can be increased when Meclizine is combined with Naltrexone.
Meprobamate
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Meprobamate.
Metamfetamine
Metamfetamine may increase the analgesic activities of Naltrexone.
Metaxalone
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Metaxalone.
Methazolamide
The therapeutic efficacy of Methazolamide can be decreased when used in combination with Naltrexone.
Methocarbamol
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Methocarbamol.
Methscopolamine bromide
The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Naltrexone.
Methylene blue
The risk or severity of hypotension and CNS depression can be increased when Methylene blue is combined with Naltrexone.
Metolazone
The therapeutic efficacy of Metolazone can be decreased when used in combination with Naltrexone.
Midazolam
The risk or severity of respiratory depression can be increased when Midazolam is combined with Naltrexone.
Milnacipran
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Milnacipran.
Mitapivat
The metabolism of Naltrexone can be increased when combined with Mitapivat.
Naldemedine
The therapeutic efficacy of Naltrexone can be decreased when used in combination with Naldemedine.
Nalmefene
The therapeutic efficacy of Naltrexone can be decreased when used in combination with Nalmefene.
Naphazoline
Naphazoline may increase the central nervous system depressant (CNS depressant) activities of Naltrexone.
Nefazodone
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Nefazodone.
Nelfinavir
The metabolism of Naltrexone can be increased when combined with Nelfinavir.
Nicardipine
The risk or severity of adverse effects can be increased when Nicardipine is combined with Naltrexone.
Nilotinib
The metabolism of Naltrexone can be decreased when combined with Nilotinib.
Nortriptyline
The risk or severity of adverse effects can be increased when Nortriptyline is combined with Naltrexone.
Olanzapine
The risk or severity of adverse effects can be increased when Olanzapine is combined with Naltrexone.
Ombitasvir
The metabolism of Naltrexone can be decreased when combined with Ombitasvir.
Orphenadrine
The risk or severity of adverse effects can be increased when Orphenadrine is combined with Naltrexone.
Oxazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Oxazepam.
Oxybutynin
The risk or severity of adverse effects can be increased when Oxybutynin is combined with Naltrexone.
Pancuronium
The risk or severity of adverse effects can be increased when Pancuronium is combined with Naltrexone.
Paritaprevir
The metabolism of Naltrexone can be decreased when combined with Paritaprevir.
Paroxetine
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Paroxetine.
Pazopanib
The metabolism of Naltrexone can be decreased when combined with Pazopanib.
Pentobarbital
The risk or severity of adverse effects can be increased when Pentobarbital is combined with Naltrexone.
Perphenazine
The risk or severity of hypotension and CNS depression can be increased when Perphenazine is combined with Naltrexone.
Phendimetrazine
Phendimetrazine may increase the analgesic activities of Naltrexone.
Phenobarbital
The risk or severity of adverse effects can be increased when Phenobarbital is combined with Naltrexone.
Phentermine
Phentermine may increase the analgesic activities of Naltrexone.
Phenytoin
The metabolism of Naltrexone can be increased when combined with Phenytoin.
Pibrentasvir
The metabolism of Naltrexone can be decreased when combined with Pibrentasvir.
Polythiazide
The therapeutic efficacy of Polythiazide can be decreased when used in combination with Naltrexone.
Potassium
The therapeutic efficacy of Potassium can be decreased when used in combination with Naltrexone.
Potassium cation
The therapeutic efficacy of Potassium cation can be decreased when used in combination with Naltrexone.
Potassium citrate
The therapeutic efficacy of Potassium citrate can be decreased when used in combination with Naltrexone.
Pregabalin
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Pregabalin.
Primidone
The risk or severity of adverse effects can be increased when Primidone is combined with Naltrexone.
Probenecid
The metabolism of Naltrexone can be decreased when combined with Probenecid.
Procaine
The risk or severity of adverse effects can be increased when Procaine is combined with Naltrexone.
Prochlorperazine
The risk or severity of hypotension and CNS depression can be increased when Prochlorperazine is combined with Naltrexone.
Promethazine
The risk or severity of adverse effects can be increased when Promethazine is combined with Naltrexone.
Propantheline
The risk or severity of adverse effects can be increased when Propantheline is combined with Naltrexone.
Propofol
Naltrexone may increase the sedative activities of Propofol.
Pseudoephedrine
Pseudoephedrine may increase the analgesic activities of Naltrexone.
Quazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Quazepam.
Quetiapine
The risk or severity of adverse effects can be increased when Quetiapine is combined with Naltrexone.
Quinidine
The risk or severity of adverse effects can be increased when Quinidine is combined with Naltrexone.
Quinine
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Quinine.
Quizartinib
The metabolism of Naltrexone can be decreased when combined with Quizartinib.
Regorafenib
The metabolism of Naltrexone can be decreased when combined with Regorafenib.
Remimazolam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Remimazolam.
Repotrectinib
The metabolism of Naltrexone can be decreased when combined with Repotrectinib.
Revefenacin
The risk or severity of adverse effects can be increased when Revefenacin is combined with Naltrexone.
Rifampin
The metabolism of Naltrexone can be increased when combined with Rifampicin.
Ritonavir
The metabolism of Naltrexone can be increased when combined with Ritonavir.
Rocuronium
The risk or severity of adverse effects can be increased when Rocuronium is combined with Naltrexone.
Samidorphan
The therapeutic efficacy of Naltrexone can be decreased when used in combination with Samidorphan.
Scopolamine
The risk or severity of adverse effects can be increased when Scopolamine is combined with Naltrexone.
Secobarbital
The risk or severity of adverse effects can be increased when Secobarbital is combined with Naltrexone.
Sertraline
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Sertraline.
Solifenacin
The risk or severity of adverse effects can be increased when Solifenacin is combined with Naltrexone.
Sorafenib
The metabolism of Naltrexone can be decreased when combined with Sorafenib.
Spironolactone
The therapeutic efficacy of Spironolactone can be decreased when used in combination with Naltrexone.
Temazepam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Temazepam.
Testosterone propionate
The metabolism of Naltrexone can be increased when combined with Testosterone propionate.
Thioridazine
The risk or severity of hypotension and CNS depression can be increased when Thioridazine is combined with Naltrexone.
Thonzylamine
The risk or severity of adverse effects can be increased when Thonzylamine is combined with Naltrexone.
Ticagrelor
Naltrexone can cause a decrease in the absorption of Ticagrelor resulting in a reduced serum concentration and potentially a decrease in efficacy.
Tiotropium
The risk or severity of adverse effects can be increased when Tiotropium is combined with Naltrexone.
Tipranavir
The metabolism of Naltrexone can be increased when combined with Tipranavir.
Tizanidine
The risk or severity of respiratory depression can be increased when Naltrexone is combined with Tizanidine.
Tolterodine
The risk or severity of adverse effects can be increased when Tolterodine is combined with Naltrexone.
Tolvaptan
The therapeutic efficacy of Tolvaptan can be decreased when used in combination with Naltrexone.
Torasemide
The therapeutic efficacy of Torasemide can be decreased when used in combination with Naltrexone.
Trazodone
The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Trazodone.
Triamterene
The therapeutic efficacy of Triamterene can be decreased when used in combination with Naltrexone.
Triazolam
The risk or severity of adverse effects can be increased when Naltrexone is combined with Triazolam.
Trifluoperazine
The risk or severity of hypotension and CNS depression can be increased when Trifluoperazine is combined with Naltrexone.
Trihexyphenidyl
The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Naltrexone.
Trospium
The risk or severity of adverse effects can be increased when Trospium is combined with Naltrexone.
Umeclidinium
The risk or severity of adverse effects can be increased when Umeclidinium is combined with Naltrexone.
Valoctocogene roxaparvovec
The therapeutic efficacy of Valoctocogene roxaparvovec can be decreased when used in combination with Naltrexone.
Valproic acid
The metabolism of Naltrexone can be decreased when combined with Valproic acid.
Vecuronium
The risk or severity of adverse effects can be increased when Vecuronium is combined with Naltrexone.
Zidovudine
The metabolism of Naltrexone can be increased when combined with Zidovudine.
Ziprasidone
The risk or severity of adverse effects can be increased when Ziprasidone is combined with Naltrexone.
Zonisamide
The therapeutic efficacy of Zonisamide can be decreased when used in combination with Naltrexone.
Acamprosate
The bioavailability of Acamprosate can be increased when combined with Naltrexone.
Bisacodyl
The therapeutic efficacy of Bisacodyl can be decreased when used in combination with Naltrexone.
Calcium polycarbophil
The therapeutic efficacy of Calcium polycarbophil can be decreased when used in combination with Naltrexone.
Carboxymethylcellulose
The therapeutic efficacy of Carboxymethylcellulose can be decreased when used in combination with Naltrexone.
Castor oil
The therapeutic efficacy of Castor oil can be decreased when used in combination with Naltrexone.
Desmopressin
The risk or severity of hyponatremia can be increased when Naltrexone is combined with Desmopressin.
Dipotassium phosphate
The therapeutic efficacy of Dipotassium phosphate can be decreased when used in combination with Naltrexone.
Docusate
The therapeutic efficacy of Docusate can be decreased when used in combination with Naltrexone.
Frangula purshiana bark
The therapeutic efficacy of Frangula purshiana bark can be decreased when used in combination with Naltrexone.
Gluconic Acid
The therapeutic efficacy of Gluconic Acid can be decreased when used in combination with Naltrexone.
Glycerin
The therapeutic efficacy of Glycerin can be decreased when used in combination with Naltrexone.
Lactitol
The therapeutic efficacy of Lactitol can be decreased when used in combination with Naltrexone.
Lactulose
The therapeutic efficacy of Lactulose can be decreased when used in combination with Naltrexone.
Leflunomide
The risk or severity of liver damage can be increased when Naltrexone is combined with Leflunomide.
Linaclotide
The therapeutic efficacy of Linaclotide can be decreased when used in combination with Naltrexone.
Lubiprostone
The therapeutic efficacy of Lubiprostone can be decreased when used in combination with Naltrexone.
Magnesium
The therapeutic efficacy of Magnesium can be decreased when used in combination with Naltrexone.
Magnesium acetate
The therapeutic efficacy of Magnesium acetate can be decreased when used in combination with Naltrexone.
Magnesium carbonate
The therapeutic efficacy of Magnesium carbonate can be decreased when used in combination with Naltrexone.
Magnesium citrate
The therapeutic efficacy of Magnesium citrate can be decreased when used in combination with Naltrexone.
Magnesium glycinate
The therapeutic efficacy of Magnesium glycinate can be decreased when used in combination with Naltrexone.
Magnesium hydroxide
The therapeutic efficacy of Magnesium hydroxide can be decreased when used in combination with Naltrexone.
Magnesium oxide
The therapeutic efficacy of Magnesium oxide can be decreased when used in combination with Naltrexone.
Magnesium sulfate
The therapeutic efficacy of Magnesium sulfate can be decreased when used in combination with Naltrexone.
Magnesium trisilicate
The therapeutic efficacy of Magnesium trisilicate can be decreased when used in combination with Naltrexone.
Methylcellulose
The therapeutic efficacy of Methylcellulose can be decreased when used in combination with Naltrexone.
Metoclopramide
The therapeutic efficacy of Naltrexone can be increased when used in combination with Metoclopramide.
Mineral oil
The therapeutic efficacy of Mineral oil can be decreased when used in combination with Naltrexone.
Monopotassium phosphate
The therapeutic efficacy of Monopotassium phosphate can be decreased when used in combination with Naltrexone.
Pegvisomant
The therapeutic efficacy of Pegvisomant can be decreased when used in combination with Naltrexone.
Picosulfuric acid
The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Naltrexone.
Plantago seed
The therapeutic efficacy of Plantago seed can be decreased when used in combination with Naltrexone.
Plecanatide
The therapeutic efficacy of Plecanatide can be decreased when used in combination with Naltrexone.
Polyethylene glycol
The therapeutic efficacy of Polyethylene glycol can be decreased when used in combination with Naltrexone.
Potassium bitartrate
The therapeutic efficacy of Potassium bitartrate can be decreased when used in combination with Naltrexone.
Potassium sulfate
The therapeutic efficacy of Potassium sulfate can be decreased when used in combination with Naltrexone.
Prucalopride
The therapeutic efficacy of Prucalopride can be decreased when used in combination with Naltrexone.
Senna leaf
The therapeutic efficacy of Senna leaf can be decreased when used in combination with Naltrexone.
Sennosides
The therapeutic efficacy of Sennosides can be decreased when used in combination with Naltrexone.
Sodium ascorbate
The therapeutic efficacy of Sodium ascorbate can be decreased when used in combination with Naltrexone.
Sodium cation
The therapeutic efficacy of Sodium cation can be decreased when used in combination with Naltrexone.
Sodium fluorophosphate
The therapeutic efficacy of Sodium fluorophosphate can be decreased when used in combination with Naltrexone.
Sodium phosphate, dibasic
The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Naltrexone.
Sodium phosphate, dibasic, unspecified form
The therapeutic efficacy of Sodium phosphate, dibasic, unspecified form can be decreased when used in combination with Naltrexone.
Sodium phosphate, monobasic
The therapeutic efficacy of Sodium phosphate, monobasic can be decreased when used in combination with Naltrexone.
Sodium phosphate, monobasic, unspecified form
The therapeutic efficacy of Sodium phosphate, monobasic, unspecified form can be decreased when used in combination with Naltrexone.
Sodium sulfate
The therapeutic efficacy of Sodium sulfate can be decreased when used in combination with Naltrexone.
Sorbitol
The therapeutic efficacy of Sorbitol can be decreased when used in combination with Naltrexone.
Succinylcholine
The risk or severity of bradycardia can be increased when Succinylcholine is combined with Naltrexone.
Sulfate ion
The therapeutic efficacy of Sulfate ion can be decreased when used in combination with Naltrexone.
Tegaserod
The therapeutic efficacy of Tegaserod can be decreased when used in combination with Naltrexone.
Teriflunomide
The risk or severity of liver damage can be increased when Naltrexone is combined with Teriflunomide.